PharmaCell to Purchase Cell Therapy Production Facility from TiGenix - - BioPharm International

ADVERTISEMENT

PharmaCell to Purchase Cell Therapy Production Facility from TiGenix



PharmaCell B.V., a CMO for cellular therapies and regenerative medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its therapy production facility at the Chemelot site in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product for cartilage repair, ChondroCelect. TiGenix and PharmaCell have signed an agreement to purchase the shares of TiGenix B.V., which holds the manufacturing site, subject to certain closing conditions and intend to close the transaction in the coming months. PharmaCell will acquire the facility, including its employees in Production, QC, QA and other functions. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with PharmaCell.

Source: PharmaCell B.V.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here